The Blood-Brain Barrier: Biology's Most Selective Gatekeeper
The blood-brain barrier (BBB) is a selective permeability boundary formed by the endothelial cells lining cerebral blood vessels. It protects the central nervous system from pathogens, toxins, and fluctuations in blood chemistry — but it also blocks most peptides from reaching brain tissue. For neuroscience researchers working with neuroactive peptides, understanding BBB transport is essential for designing protocols that achieve meaningful CNS exposure.
BBB Structure and Why It Blocks Peptides
The BBB isn't a single structure — it's a system of physical and biochemical barriers:
- Tight junctions: Endothelial cells are sealed together by claudin, occludin, and ZO proteins, creating junctions 50-100 times tighter than peripheral capillaries. Paracellular (between-cell) transport is essentially zero.
- Efflux transporters: P-glycoprotein (P-gp) and other ABC transporters actively pump foreign molecules back into the bloodstream, even after they cross the membrane.
- Enzymatic barrier: Peptidases in the endothelium degrade many peptides before they can cross completely.
- Low pinocytosis: Brain endothelial cells have minimal vesicular transport compared to peripheral vessels.
The combined effect: approximately 98% of small-molecule drugs and nearly 100% of large-molecule therapeutics (including most peptides) do not cross the BBB at pharmacologically relevant concentrations (Pardridge, 2005).
Transport Mechanisms for Peptides
Despite these barriers, certain peptides do reach the CNS through several mechanisms:
1. Passive Transcellular Diffusion
Small, lipophilic molecules can dissolve through the endothelial cell membranes. Requirements:
- Molecular weight under ~400-500 Da
- Fewer than 8-10 hydrogen bond donors
- Sufficient lipophilicity (Log P > 1)
Very few peptides meet these criteria due to the polar nature of peptide bonds and amino acid side chains.
2. Receptor-Mediated Transcytosis (RMT)
Peptides that bind specific receptors on the luminal surface of brain endothelial cells can be transported across in vesicles. Key receptors include:
- Transferrin receptor: Used to shuttle iron-bound transferrin
- LRP1 (Low-density lipoprotein receptor-related protein 1): Transports multiple ligands including melanotransferrin and certain peptides
- Insulin receptor: Transports insulin across the BBB
3. Adsorptive-Mediated Transcytosis (AMT)
Positively charged (cationic) peptides interact electrostatically with the negatively charged endothelial surface, triggering vesicular uptake. This mechanism is charge-dependent rather than receptor-specific, offering a broader but less selective pathway.
4. Carrier-Mediated Transport (CMT)
Specific transporters shuttle amino acids, small peptides, and peptide-like molecules across the BBB. The large neutral amino acid transporter (LAT1) and the peptide transporter (PepT) family are examples. Some di- and tri-peptides can piggyback on these systems.
5. Circumventricular Organs
Several brain regions lack a complete BBB, including the area postrema, median eminence, and subfornical organ. Peptides in the bloodstream can access these regions directly, where they influence adjacent brain structures through volume transmission.
BBB-Permeable Research Peptides
Semax (MEHFPGP, MW 813.9 Da)
Semax is a synthetic analog of ACTH(4-10) with a Pro-Gly-Pro C-terminal extension that confers resistance to enzymatic degradation. Research indicates CNS penetration through:
- Intranasal delivery bypassing the BBB via olfactory nerve pathways
- Some evidence of peripheral-to-central transport, possibly via AMT (the molecule carries a net positive charge at physiological pH)
- Studies in rodents demonstrate increased BDNF expression in hippocampus after nasal administration (Dolotov et al., 2006)
Selank (TKPRPGP, MW 751.9 Da)
Selank is based on the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Gly-Pro extension. Like Semax, it is primarily administered intranasally for CNS research. Studies report anxiolytic-like effects in animal models, suggesting functional CNS access (Seredenin et al., 2001).
Dihexa (MW 507.6 Da)
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a modified angiotensin IV analog designed for enhanced BBB permeability. Key features:
- Molecular weight near the passive diffusion threshold
- Hexanoic acid modifications increase lipophilicity
- Binds hepatocyte growth factor (HGF) receptor with high affinity
- Studies by Benoist et al. (2012) reported cognitive enhancement in aged rats, suggesting effective CNS penetration
DSIP (Delta Sleep-Inducing Peptide, MW 848.8 Da)
This nonapeptide has been reported to cross the BBB in small amounts via a non-saturable mechanism, suggesting passive transport enhanced by its relatively compact structure.
Epithalon (AEDG, MW 390.3 Da)
This tetrapeptide's small size (390 Da) places it below the passive diffusion threshold. While direct BBB penetration studies are limited, its small MW and relatively simple structure suggest possible passive transport.
Nasal Delivery: Bypassing the BBB Entirely
Intranasal administration offers a route to the CNS that circumvents the BBB altogether. This pathway exploits the anatomy of the nasal cavity:
Two Pathways to the Brain
- Olfactory pathway: Peptides deposited on the olfactory epithelium (upper nasal cavity) are transported along olfactory nerve axons directly to the olfactory bulb and beyond. Transit time: 15-60 minutes in animal models.
- Trigeminal pathway: Peptides absorbed by trigeminal nerve endings in the nasal mucosa travel along branches to the brainstem and pons.
Peptides Studied via Nasal Delivery
| Peptide | MW (Da) | Nasal Bioavailability | Key Research Finding |
|---|---|---|---|
| Semax | 813.9 | Moderate-high | Increased BDNF in hippocampus within 30 min |
| Selank | 751.9 | Moderate-high | Anxiolytic effects comparable to benzodiazepines |
| NAD+ | 663.4 | Under investigation | Direct CNS delivery of NAD+ precursors studied |
| Insulin | 5,808 | Low-moderate | Improved memory in human trials (Born et al., 2002) |
| Oxytocin | 1,007 | Low-moderate | Social behavior modulation in humans |
Nasal vs Injection for CNS Peptides
| Factor | Nasal Spray | SC/IM Injection |
|---|---|---|
| BBB bypass | Yes (olfactory/trigeminal) | No — must cross BBB |
| Onset to CNS | 15-30 minutes | Dependent on BBB permeability |
| Systemic exposure | Lower | Higher |
| Dosing precision | Moderate (spray variability) | High |
| Non-invasive | Yes | No |
| Mucosal irritation risk | Possible with repeated use | Not applicable |
Implications for Research Design
When designing experiments with neuroactive peptides, the delivery route must match the research question. Systemic injection of a peptide that doesn't cross the BBB will produce peripheral effects but no direct CNS action. Conversely, intranasal delivery maximizes CNS exposure but limits peripheral tissue distribution. Understanding these dynamics ensures that experimental outcomes reflect the peptide's actual CNS activity rather than delivery artifacts.
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.